Free delivery over $100 Learn more

30 days return period Learn more
SKU: 0237ATC

LNCaP, clone FGC Human Epithelial Cells

Tumor Cell Lines > Prostate Cancer Cell Lines

Product Type: Human Prostate Cancer Cell Lines

Species: Human

Cell Type: Epithelial Cells

Source Organ: Lymphatic System

$1,249.00
Size

Care information

Display general product information or specific product information using metafields.

Delivery and Shipping

Add some general information about your delivery and shipping policies.

Cell Name: LNCaP, clone FGC

LNCaP clone FGC was isolated in 1977 by J.S. Horoszewicz, et al., From a needle aspiration biopsy of the left supraclavicular lymph node of a 50-year-old Caucasian male (blood type B+) with confirmed diagnosis of metastatic prostate carcinoma.

  • Description
    The LNCaP cell line was established in 1977 from a metastatic lesion in the left supraclavicular lymph node of a 50-year-old Caucasian male with prostate carcinoma. These cells grow in aggregates or as single cells, with a weak attachment to the substrate and a tendency to rapidly acidify the growth medium. LNCaP cells have a high affinity for androgen receptors and respond to hormonal stimulation. Unlike other cell lines, they do not form a uniform monolayer, instead growing in clusters that require dissociation for subculture. They are tumorigenic in immunodeficient mice and are frequently used for prostate cancer research. LNCaP cells are free from mycoplasma, bacteria, yeast, and fungi. These cells serve as an excellent in vitro model for studying prostate cancer, androgen receptor signaling, and drug resistance.
  • Product Name
    LNCaP, clone FGC
  • Product Type
    Human Prostate Cancer Cell Lines
  • Species
    Human
  • Cell Type
    Epithelial
  • Product Type
    Human Prostate Cancer Cell Lines
  • Growth Conditions
    37 °C, 5% CO2
  • Application
    The LNCaP cell line can be used to develop the CDX-type LNCaP mouse model. This model is valuable for studying androgen sensitivity, as LNCaP cells possess a mutated androgen receptor (AR T877A). The LNCaP xenograft model serves as an androgen-dependent system and is utilized for evaluating various treatment modalities targeting the androgen receptor, such as AR-targeting oligos or bicalutamide. This model provides a platform to study how well these treatments work and how they function in the context of androgen-dependent prostate cancer.
  • Size/Quantity
    1 vial
  • Recommended Medium And Supplement

    RPMI 1640 + 10% FBS
  • Shipping Conditions
    Dry Ice
  • Storage
    Liquid Nitrogen
  • Biosafety Level
    1

Payment & Security

Payment methods

    Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

    • Visit our support center

      Expert help & advice

    • Check your order status

      Updates & tracking

    • Returns & exchanges

      All you need to know

    • Price-match guarantee

      Our promise to you